Marshall Wace
CRNX icon

Marshall Wace’s Crinetics Pharmaceuticals CRNX Stock Holding History

Marshall Wace’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.8M Buy
+684,108
New +$30.6M 0.02% 618
2025
Q2 		– Sell
-9,182
Closed -$308K – 2777
2025
Q1 		$308K Buy
+9,182
New +$343K ﹤0.01% 2258
2024
Q3 		– Sell
-141,204
Closed -$6.32M – 2575
2024
Q2 		$6.32M Buy
+141,204
New +$6.52M 0.01% 913
2023
Q4 		– Sell
-29,500
Closed -$877K – 2232
2023
Q3 		$877K Buy
+29,500
New +$608K ﹤0.01% 1542
2022
Q1 		– Sell
-445
Closed -$12K – 3447
2021
Q4 		$12K Buy
+445
New +$11K ﹤0.01% 3740
2020
Q2 		– Sell
-4,246
Closed -$62K – 1610
2020
Q1 		$62K Buy
+4,246
New +$87K ﹤0.01% 1395
2019
Q4 		– Sell
-55,112
Closed -$829K – 1754
2019
Q3 		$829K Buy
55,112
+20,874
+61% +$406K 0.01% 988
2019
Q2 		$857K Buy
34,238
+176
+0.5% +$4.36K 0.01% 970
2019
Q1 		$775K Buy
+34,062
New +$837K 0.01% 1013

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Marshall Wace's CRNX Position: Q1 2026 in Review

Marshall Wace opened a new position in Crinetics Pharmaceuticals (CRNX) in Q1 2026: 684,108 shares worth $24.8M. The stake represents 0.02% of the portfolio and ranks #618 among its holdings. This is a return to the name: Marshall Wace previously reported a position in CRNX as recently as Q1 2025.

Marshall Wace first reported a position in CRNX in Q1 2019 and has held it in 9 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Marshall Wace held 684,108 shares of Crinetics Pharmaceuticals worth $24.8M as of Q1 2026.
  • Crinetics Pharmaceuticals was a new Marshall Wace position in Q1 2026.
  • Crinetics Pharmaceuticals made up 0.02% of Marshall Wace's portfolio in Q1 2026, its #618 holding.
  • Marshall Wace first reported a position in Crinetics Pharmaceuticals in Q1 2019 and has held it in 9 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.